3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
6
NIH
2
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
11
Neuroblastoma
7
Lymphoma
7
Neoplasms, Plasma Cell
5
Immunoglobulin Light-chain Amyloidosis
5
Hodgkin Disease
4
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Myelodysplastic Syndromes
3
Leukemia, Myeloid, Acute
3
Leukemia, Lymphocytic, Chronic, B-Cell
3
Leukemia, Biphenotypic, Acute
3
Leukemia
3
Ganglioneuroblastoma
3
Waldenstrom Macroglobulinemia
2
Sarcoma, Ewing
2
Preleukemia
2
Precancerous Conditions
2
Neoplasms by Histologic Type
2
Neoplasms
2
Lymphoproliferative Disorders
2
Lymphoma, Mantle-Cell
2
Lymphoma, Follicular
2
Lymphatic Diseases
2
Leukemia, Myeloid
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Leukemia, Lymphoid
2
Leukemia, B-Cell
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Hematologic Diseases
2
Interventions
pomalidomide
1
isatuximab
1
Melphalan
1
Dexamethasone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
NETWORK
×
Amyloidosis
×
Melphalan
×
Clear all
NCT01277016
2017-03-10
EMN-03
European Myeloma Network B.V.
Phase 3
Completed
110 enrolled